Biocon Limited has informed the Exchange regarding a press release dated September 17, 2025, titled "Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya and Aukelso , Denosumab Biosimilars".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon's subsidiary Biocon Biologics has received approval from the U.S. Food and Drug Administration (USFDA) for two new biosimilar products, Bosaya and Aukelso. These are biosimilar versions of Denosumab, a drug commonly used to treat osteoporosis and certain bone-related conditions. With this approval, Biocon Biologics becomes one of the early players with approved Denosumab biosimilars for the U.S. market. The approval paves the way for the company to commercially launch these products in the United States, one of the world's largest pharmaceutical markets. This adds to Biocon Biologics' growing portfolio of biosimilars approved in regulated markets.
This is a positive development for Biocon shareholders as USFDA approval unlocks access to the large and lucrative U.S. biosimilars market, potentially driving future revenue and earnings growth for Biocon Biologics. Near-term stock reaction is likely to be positive, though commercial uptake will depend on launch timelines, pricing, and competition.